Compare BridgeBio Pharma Inc (BBIO) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs VanEck Rare Earth/Strategic Metals — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while VanEck Rare Earth/Strategic Metals trades at $77.84. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals.
| BBIO | REMX | |
|---|---|---|
Market Cap | $16.61B | — |
Sector | Health | Sector/Thematic |
52-Week High | $90.17 | $109.53 |
52-Week Low | $47.29 | $56.60 |
Enterprise Value | $18.16B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $77.04, up 4.93% in the past 24 hours, reflecting strong momentum amid bullish technical signals. The ETF's high volatility (~50% annualized) and exposure to rare earth metals, critical for technology and defense, align with recent U.S. policy shifts to secure supply chains. However, key financial ratios like P/E and P/S are unavailable, limiting fundamental clarity. Support levels are clustered near $76-$77, with resistance at $78-$79, indicating a tight trading range.
Outlook hinges on geopolitical trends favoring rare earth independence from China, but risks include extreme volatility and China-dominated holdings. Analyst sentiment is mixed, with technical indicators suggesting near-term strength but overbought conditions. Investors should weigh the ETF's strategic theme against its suitability for conservative portfolios.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →
